Orchid Chemicals & Pharmaceuticals has entered into an out-licensing and distribution agreement with the US-based pharma company Alvogen for marketing eight of Orchid's oral non-antibiotic generic formulations in the
Orchid will develop and manufacture eight oral non-antibiotic formulations for licensing to and marketing by Alvogen in the
Alvogen would pay certain dossier licence fees to Orchid based on development and regulatory milestones and share profits arising from marketing of these products in the
These formulations licensed to Alvogen under the agreement comprise products in the high-growth therapeutic segments of CNS and Osteoporosis among others. The combined addressable market size of these products is around $8 billion.
crackcrack
